Tailoring DNA vaccines: designing strategies against HER2 positive cancers

Tailoring DNA vaccines: designing strategies against HER2 positive cancers

The crucial role of HER2 in epithelial transformation and its selective overexpression on cancer tissues makes it an ideal target for cancer immunotherapies such as passive immunotherapy with Trastuzumab. There are, however, a number of concerns regarding the use of monoclonal antibodies which inclu...

Full description

Bibliographic Details
Main Authors:	Cristina eMarchini, Cristina eKalogris, Chiara eGarulli, lucia ePietrella, Federico eGabrielli, Claudia eCurcio, Elena eQuaglino, Federica eCavallo, Augusto eAmici
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-05-01
Series:	Frontiers in Oncology
Subjects:	Immunotherapy breast cancer HER2 immunological tolerance DNA Vaccines
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00122/full

Similar Items

The potential of panHER inhibition in cancer
by: Xiaochun eWang, et al.
Published: (2015-01-01)

Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).
by: Federico Gabrielli, et al.
Published: (2013-01-01)

HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
by: Junbiao Wang, et al.
Published: (2022-08-01)

Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues
by: Anna eSapino, et al.
Published: (2013-05-01)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
by: Giovanni Almadori, et al.
Published: (2021-09-01)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
by: Shayalini Wignarajah, et al.
Published: (2023-03-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Preclinical HER-2 vaccines: from rodent to human HER-2
by: Pier-Luigi eLollini, et al.
Published: (2013-06-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
by: Andrew T Baker, et al.
Published: (2014-12-01)

Ultrasensitive assay of HER1, HER2, and heregulin-α in whole blood
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-12-01)

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
by: Michelle D. Hackshaw, et al.
Published: (2021-08-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
by: Marco Macagno, et al.
Published: (2022-01-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
by: Alexander Rau, et al.
Published: (2021-01-01)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
by: Christiane Palm, et al.
Published: (2023-01-01)

Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
by: Elda eTagliabue, et al.
Published: (2014-11-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
by: Hongmei Xiao, et al.
Published: (2019-09-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
by: Vladimir I. Evdokimov, et al.
Published: (2023-12-01)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
by: Tejaswini P. Reddy, et al.
Published: (2020-05-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
by: Lena-Christin Conradi, et al.
Published: (2019-09-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

Evaluation of <sup>68</sup>Ga-Radiolabeled Peptides for HER2 PET Imaging
by: Maxwell Ducharme, et al.
Published: (2022-11-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.
by: Cristina Marchini, et al.
Published: (2011-01-01)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
by: Xiaoqing Cai, et al.
Published: (2023-06-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
by: Jeroen Claus, et al.
Published: (2018-05-01)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
by: Emilia Rabia, et al.
Published: (2021-01-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Jing Ma, et al.
Published: (2022-07-01)

FIBROBLAST INVOLVEMENT IN SOFT CONNECTIVE TISSUE CALCIFICATION
by: Ivonne eRonchetti, et al.
Published: (2013-03-01)